Oslo, Norway, 26 May 2010
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, will be hosting a Capital Markets Day in Oslo on Wednesday 16 June at 08:30 CET.
http://w.on24.com/r.htm?e=219675&s=1&k=1652A9C4F2322B5FAEBF5D62250CFEEB
The Capital Markets Day, which will be open to analysts, investors, press and other interested parties, will include presentations from some of the Company's external research and development partners in the USA and Europe, as well as senior management (preliminary program is attached).
The guest speakers for the event are:
- Professor Alan Burnett, Head of Haematology at the Department of Medical Genetics, Haematology & Pathology at Cardiff University School of Medicine, UK. Prof. Burnett is a leading expert in acute myeloid leukaemia and will provide a clinician's view of current treatment options and the need for more effective new therapies.
- Patrick Mahaffy, CEO of Clovis Oncology Inc. Mr Mahaffy will present a view on Clovis Oncology's strategic partnership with Clavis Pharma for the cancer drug CP-4126, the clinical development programme in pancreatic cancer and other potential indications, and also the development of a companion diagnostic, which is aimed at identifying patients most likely to benefit from treatment with CP-4126.
- Dr. Tone Ikdahl, Head of Gastrointestinal- and uro-oncology Unit at the Department of Oncology, Oslo University Hospital, is the coordinating investigator for the Phase II program for CP-4126 in pancreatic cancer in Europe and will give valuable clinical insight into the need for better treatment for pancreatic cancer patients.
Participants will also hear from members of Clavis Pharma's senior management team on the Company, its LVT technology platform for creating new, improved versions of successful cancer drugs, development strategy, market opportunity, as well as an update on the Company's recent activities.
The meeting will be webcast and will be available on 16 June,
from 08:30 CET, at www.clavispharma.com/webcast.
To register, please contact: Bente Y. Robertsen
bente.robertsen@clavispharma.com
For further information contact:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
+44 7833904901 (UK mob)
olav.hellebo@clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology drug development company based in Oslo, Norway with a portfolio of novel anti-cancer
drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful
drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough
products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue
penetration, altered metabolism and, in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
- Elacytarabine, an improved form of Ara-C, a leukaemia drug - about to commence a Phase III randomized, controlled registration study in late-stage acute myeloid leukaemia;
- Intravenous CP-4126, an improved version of gemcitabine - currently in a Phase II comparative study with gemcitabine for the treatment of pancreatic cancer;
- CP-4200, an azacitidine derivative - in preclinical development for myelodysplastic syndrome (MDS), often a precursor to myeloma or leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. CP-4126 is licensed to Clovis Oncology in the Americas and Europe. Clavis Pharma has retained rights in other territories and an option to co-promote CP-4126 in Europe.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker: CLAVIS). s